Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice.



Ritchie, Leona A ORCID: 0000-0002-0392-1767, Qin, Shuguang, Penson, Peter E, Henney, Neil C ORCID: 0000-0002-2834-1566 and Lip, Gregory Yh
(2020) Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. Future cardiology, 16 (6). 585 - 595.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Vernakalant is an intravenous anti-arrhythmic drug available in Europe, Canada and some countries in Asia for the restoration of sinus rhythm in acute onset atrial fibrillation. Currently, it is not available in USA because the US FDA have ongoing concerns about its safety. Vernakalant has a unique pharmacological profile of multi-ion channel activity and atrial-specificity that distinguishes it from other anti-arrhythmic drugs. This is thought to enhance efficacy but there are concerns of adverse events stemming from its diverse pharmacology. This ambiguity has prompted a review of the available clinical evidence on efficacy and safety to help re-evaluate its place in clinical practice.

Item Type: Article
Uncontrolled Keywords: Humans, Atrial Fibrillation, Anisoles, Pyrrolidines, Anti-Arrhythmia Agents
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 06 Jul 2021 08:30
Last Modified: 10 Jun 2022 00:18
DOI: 10.2217/fca-2020-0039
Open Access URL: https://researchonline.ljmu.ac.uk/id/eprint/12861/
URI: https://livrepository.liverpool.ac.uk/id/eprint/3128976